» Articles » PMID: 32158479

Motion Sickness: an Overview

Overview
Journal Drugs Context
Specialty Pharmacology
Date 2020 Mar 12
PMID 32158479
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Motion sickness is a common phenomenon that affects almost everybody at some point in their lifetime. Clinicians should be familiar with the proper management of this condition.

Objective: To provide an update on the current understanding of the pathophysiology and management of motion sickness.

Methods: A PubMed search was performed with Clinical Queries using the key term 'motion sickness.' The search strategy included meta-analyses, randomized controlled trials, clinical trials, observational studies, and reviews. The search was restricted to English literature. The information retrieved from the earlier search was used in the compilation of the present article.

Results: Motion sickness is typically triggered by low-frequency vertical, lateral, angular, rotary motion, or virtual stimulator motion, to which an individual has not adapted. for developing motion sickness is when the brain receives conflicting information from different sensors about real body movements or virtual environment. The principal sensors are the eyes, the vestibular apparatus, and proprioceptive receptors. The conflicting information is judged in relation to a pattern of expected associations formed under normal or experienced conditions stored in the brain. Motion sickness typically presents with malaise, anorexia, nausea, yawning, sighing, increased salivation, burping, headache, blurred vision, non-vertiginous dizziness, drowsiness, spatial disorientation, difficulty concentrating, and sometimes vomiting. Simple behavioral and environmental modifications can be effective in the prevention of motion sickness. Medications that are effective in the prophylaxis and/or treatment of motion sickness include anticholinergics, antihistamines, and sympathomimetics.

Conclusion: In most cases, motion sickness can be prevented by behavioral and environmental modifications (avoidance, habituation, and minimization of motion stimuli). Pharmacotherapy should be considered in the prevention and/or treatment of more severe motion sickness and for patients who do not respond to conservative measures. Medications are most effective when combined with behavioral and environmental modifications. Drugs that are effective in the prophylaxis and/or treatment of motion sickness include anticholinergic agents and antihistamines.

Citing Articles

Ear, nose and throat disorders and international travel.

McHugh N, Lyons R, Keogh I, Flaherty G Trop Dis Travel Med Vaccines. 2025; 11(1):3.

PMID: 39953586 PMC: 11829402. DOI: 10.1186/s40794-024-00238-9.


Psychometric properties of the Turkish version of the Vestibular Migraine Patient Assessment Tool and Handicap Inventory.

Cengiz D, Inceoglu F, Karababa E, Satar B, Erbek H, Bayindir T Turk J Med Sci. 2024; 54(5):979-988.

PMID: 39473743 PMC: 11518351. DOI: 10.55730/1300-0144.5876.


Neuro-ophthalmic and Neuro-otologic Evaluation in Individuals with Motion Sickness Susceptibility.

Aydin K, Kara E, Uzun Adatepe N, Atas A J Int Adv Otol. 2024; 20(4):345-350.

PMID: 39161227 PMC: 11363172. DOI: 10.5152/iao.2024.241491.


Relationship Between Motion Sickness Susceptibility and Vestibular Test Results.

Gedik Toker O, Kuru E, Ozdemir S, Rencber B, Takan E, Araz S Medeni Med J. 2024; 39(2):91-100.

PMID: 38940460 PMC: 11572269. DOI: 10.4274/MMJ.galenos.2024.08504.


Incidence and Importance of Peripheral Vestibular Dysfunction in Adolescent Idiopathic Scoliosis.

Vladareanu L, Iliescu M, Andronache I, Dantes E Children (Basel). 2024; 11(6).

PMID: 38929302 PMC: 11201755. DOI: 10.3390/children11060723.


References
1.
Stern R, Hu S, Uijtdehaage S, Muth E, Xu L, Koch K . Asian hypersusceptibility to motion sickness. Hum Hered. 1996; 46(1):7-14. DOI: 10.1159/000154318. View

2.
Turner M, Griffin M, Holland I . Airsickness and aircraft motion during short-haul flights. Aviat Space Environ Med. 2001; 71(12):1181-9. View

3.
Golding J, Gresty M . Pathophysiology and treatment of motion sickness. Curr Opin Neurol. 2014; 28(1):83-8. DOI: 10.1097/WCO.0000000000000163. View

4.
Bar R, Gil A, Tal D . Safety of double-dose transdermal scopolamine. Pharmacotherapy. 2009; 29(9):1082-8. DOI: 10.1592/phco.29.9.1082. View

5.
Qi R, Su Y, Pan L, Mao Y, Liang L, Dai Z . Anti-cholinergics mecamylamine and scopolamine alleviate motion sickness-induced gastrointestinal symptoms through both peripheral and central actions. Neuropharmacology. 2018; 146:252-263. DOI: 10.1016/j.neuropharm.2018.12.006. View